NO20005981L - Anvendelse av 2-hydroksy-4-trifluorbenzosyrederivater som inhibitorer av aktivering av den nukleære transkripsjonsfaktor NF- <kappa>B - Google Patents

Anvendelse av 2-hydroksy-4-trifluorbenzosyrederivater som inhibitorer av aktivering av den nukleære transkripsjonsfaktor NF- <kappa>B

Info

Publication number
NO20005981L
NO20005981L NO20005981A NO20005981A NO20005981L NO 20005981 L NO20005981 L NO 20005981L NO 20005981 A NO20005981 A NO 20005981A NO 20005981 A NO20005981 A NO 20005981A NO 20005981 L NO20005981 L NO 20005981L
Authority
NO
Norway
Prior art keywords
kappa
hydroxy
activation
acid derivatives
inhibitors
Prior art date
Application number
NO20005981A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005981D0 (no
Inventor
Manuel Merlos Roca
Alberto Fernandez De Arriba
Fernando Cavalcanti De Maria
Augusti Miralles Acosta
Mariano Sanchez Crespo
Julian Garcia Rafanell
Javier Forn Dalmau
Original Assignee
Uriach & Cia Sa J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uriach & Cia Sa J filed Critical Uriach & Cia Sa J
Publication of NO20005981D0 publication Critical patent/NO20005981D0/no
Publication of NO20005981L publication Critical patent/NO20005981L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20005981A 1998-05-27 2000-11-27 Anvendelse av 2-hydroksy-4-trifluorbenzosyrederivater som inhibitorer av aktivering av den nukleære transkripsjonsfaktor NF- <kappa>B NO20005981L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009801154A ES2136581B1 (es) 1998-05-27 1998-05-27 Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
PCT/ES1999/000154 WO1999061030A1 (fr) 1998-05-27 1999-05-26 UTILISATION DE DERIVES DE L'ACIDE 2-HYDROXY-4-TRIFLUOROMETHYLBENZOIQUE PERMETTANT D'INHIBER L'ACTIVATION DU FACTEUR DE TRANSCRIPTION NUCLEAIRE NF-λB

Publications (2)

Publication Number Publication Date
NO20005981D0 NO20005981D0 (no) 2000-11-27
NO20005981L true NO20005981L (no) 2000-12-12

Family

ID=8304002

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005981A NO20005981L (no) 1998-05-27 2000-11-27 Anvendelse av 2-hydroksy-4-trifluorbenzosyrederivater som inhibitorer av aktivering av den nukleære transkripsjonsfaktor NF- <kappa>B

Country Status (14)

Country Link
US (2) US6414025B1 (fr)
EP (2) EP1082962B1 (fr)
JP (1) JP2002516283A (fr)
KR (2) KR100762156B1 (fr)
AT (1) ATE245987T1 (fr)
AU (1) AU3828699A (fr)
BR (1) BR9911598A (fr)
CA (1) CA2332863A1 (fr)
DE (1) DE69910019T2 (fr)
DK (1) DK1082962T3 (fr)
ES (2) ES2136581B1 (fr)
NO (1) NO20005981L (fr)
PT (1) PT1082962E (fr)
WO (1) WO1999061030A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2154242B1 (es) * 1999-09-03 2001-10-16 Uriach & Cia Sa J Nuevos sistemas polimericos biocompatibles portadores de triflusal o htb.
US20040101488A1 (en) * 2000-03-24 2004-05-27 Balaram Ghosh Method for the prevention of septic shock lethality using curcumin
ES2190373B1 (es) * 2001-12-07 2004-10-16 J. URIACH &amp; CIA, S.A. Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.
JP2006502183A (ja) 2002-09-20 2006-01-19 アルコン，インコーポレイテッド ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用
US8207151B2 (en) 2008-05-28 2012-06-26 Validus Biopharma Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
JP5795304B2 (ja) 2009-03-18 2015-10-14 レスバーロジックス コーポレイション 新規抗炎症剤
EP2556083A4 (fr) 2010-04-05 2013-12-04 Validus Biopharma Inc Modulateurs stéroïdes non hormonaux de nf- kappa b pour le traitement de maladies
CN103665012B (zh) * 2013-12-06 2016-06-22 辽宁师范大学 新型三氟柳无机药物化合物及合成方法
WO2017004205A1 (fr) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. Modulateurs stéroïdiens non hormonaux de nf-κb pour le traitement de maladies
US20180016314A1 (en) * 2016-07-12 2018-01-18 Children's Hospital Medical Center Treatment of disease via transcription factor modulation
KR101975603B1 (ko) 2018-09-14 2019-08-28 이영문 조력 발전장치
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4096252A (en) * 1976-06-10 1978-06-20 J. Uriach & Cia S.A. 4-Trifluoromethylbenzoic acid derivatives as thromboembolic agents
IT1276071B1 (it) * 1995-10-31 1997-10-24 Nicox Ltd Compositi ad attivita' anti-infiammatoria

Also Published As

Publication number Publication date
AU3828699A (en) 1999-12-13
KR20070006943A (ko) 2007-01-11
US20030032630A1 (en) 2003-02-13
EP1082962B1 (fr) 2003-07-30
NO20005981D0 (no) 2000-11-27
ES2136581B1 (es) 2000-09-16
JP2002516283A (ja) 2002-06-04
WO1999061030A1 (fr) 1999-12-02
DK1082962T3 (da) 2003-11-24
KR20010052404A (ko) 2001-06-25
CA2332863A1 (fr) 1999-12-02
US6414025B1 (en) 2002-07-02
DE69910019D1 (de) 2003-09-04
EP1082962A1 (fr) 2001-03-14
ES2136581A1 (es) 1999-11-16
KR100762156B1 (ko) 2007-10-04
PT1082962E (pt) 2003-11-28
ES2204129T3 (es) 2004-04-16
KR100713601B1 (ko) 2007-05-02
BR9911598A (pt) 2001-02-13
ATE245987T1 (de) 2003-08-15
EP1362592A1 (fr) 2003-11-19
DE69910019T2 (de) 2004-05-06
US6610745B2 (en) 2003-08-26

Similar Documents

Publication Publication Date Title
BR0009814A (pt) Processo para tratar de uma doença associada com o receptor-beta estrogênico
BR9806752A (pt) Ftalazinonas.
JP2000503980A5 (fr)
NO20005981L (no) Anvendelse av 2-hydroksy-4-trifluorbenzosyrederivater som inhibitorer av aktivering av den nukleære transkripsjonsfaktor NF- &lt;kappa&gt;B
PT921785E (pt) Combinacao de enzimas protease acidas e tampoes acidicos e suas utilizacoes
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
NO992400L (no) Nye substituerte pyrazolderivater
NO20003233D0 (no) 4-hydrokykinolin-3-karboksamider og hydraziner som antivirale midler
NO982172L (no) Anvendelse av epinastin for behandling av smerter
BR0109703A (pt) Derivados de piperazina
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
BRPI0010891B1 (pt) geração de microespuma terapêutica.
MX9204625A (es) Composicion farmaceutica para el tratamiento de una especie de mamifero, que sufre de deficiencia cardiaca congestiva.
BR0110961A (pt) Derivados de triazol
NO991732L (no) Nye heterocyklylmetylsubstituerte pyrazolderivater
BR9911040A (pt) 2-fenil-1-[4-(2-aminoetóxi)-benzil]-indol em combinação com estrogêneos
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
DK0888327T3 (da) Benzopyranderivater, som har antagonistisk virkning imod leukotriener
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
ES2191099T3 (es) Derivados de hidantoina como productos intermedios para principios activos farmaceuticos.
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
ITTO950099A0 (it) Catetere, particolarmente per il trattamento di aritmie cardiache.
CA2203463A1 (fr) Nouveaux acides et esters de la diosmetine, et les compositions pharmaceutiques les contenant
BR0206087A (pt) Formulação de enxaguamento redutora para uso com ozÈnio no tratamento de cáries dentárias

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application